Beacon Pointe Advisors, LLC Acadia Pharmaceuticals Inc Transaction History

Beacon Pointe Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$13.01 - $27.22 $80,662 - $168,764	-6,200 Reduced 17.54%	29,157 $408,000
Q1 2022 May 17, 2022	BUY	$20.94 - $27.5 $192,648 - $253,000	9,200 Added 35.17%	35,357 $856,000
Q4 2021 Feb 14, 2022	SELL	$16.79 - $27.09 $256,853 - $414,422	-15,298 Reduced 36.9%	26,157 $611,000
Q3 2021 Nov 15, 2021	SELL	$15.78 - $24.77 $144,387 - $226,645	-9,150 Reduced 18.08%	41,455 $689,000
Q2 2021 Aug 17, 2021	BUY	$19.4 - $27.42 $981,736 - $1.39 Million	50,605 New	50,605 $1.23 Million

316

164M

855K

350K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $3.18B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Beacon Pointe Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Beacon Pointe Advisors, LLC with notifications on news.